ERNA Stock — Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. (ERNA)

Updated October 16, 2026.

ERNA is a Stock. Total return is -100.0% over the past 35.1 years.

Ernexa Therapeutics is a preclinical-stage biopharmaceutical company developing induced mesenchymal stem cell therapies for cancer and autoimmune disease, with lead programs targeting ovarian cancer and rheumatoid arthritis. The company does not currently have an established distribution. This security appeals to investors with a higher risk tolerance seeking exposure to early-stage cell therapy development.

ERNA performance

Price and return data through 2026-10-16.

Total return is -100.0% over the past 35.1 years. Over the past year its total return — price change plus distributions reinvested — is -93.3%. Its deepest 1-year drawdown was 95.6%.

ERNA key facts

Asset type

Stock

Asset class

Equity

Inception date

08/29/1991

Distribution frequency

None

Last close

$2.09 (as of 2026-10-16)

Market cap

$3,411,739

Average volume

24526.0

Beta

2.646

Payout ratio

0.0%

EPS

$-13.63

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ERNA risks and drawbacks

The deepest 1-year drawdown on record here is 95.6%.

Who may consider ERNA — and who may not

It is a weaker fit for investors who need monthly cash flow (ERNA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ERNA

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions